AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34113094
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (1mg) in stable COPD
Trial: 34113094
Drug: Inhaled nemiralisib
RxNorm normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nemiralisib (1mg) in AECOPD
Trial: 33319866
Drug: Ramelteon (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon (0.1 mg kg-1 dissolved in 5 mL of lactose-containing syrup)
Trial: 33319866
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same amount of syrup alone)
Trial: 34306265
Drug: LABA +
RxNorm normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA + inhaled corticosteroid (formoterol/budesonide)
Trial: 34306265
Drug: LAMA +
RxNorm normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMA + inhaled corticosteroid (tiotropium/budesonide)
Trial: 35032204
Drug: Gastrotuss® (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrotuss® (20 ml, three daily doses)
Trial: 35032204
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg, once daily)
Trial: 34455728
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with rose essential oil (REO), 3 drops by inhalation, three times a day for 3 days
Trial: 34455728
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 drops by inhalation, three times a day for 3 days
Trial: 32927487
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 μg pills, 2 pills daily for 4 weeks)
Trial: 32482534
Drug: Adjuvant mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5‐FU bolus 400 mg/m² then 5FU Continuous infusion 2.4 g/m²) every two weeks for 12 cycles
Trial: 33864109
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (OT) performed twice a day
Trial: 32969384
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy (furosemide infusion at 2mg/hour and albumin at 2g/hour for three days)
Trial: 32969384
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy (intravenous albumin and furosemide as boluses)
Trial: 34424102
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management techniques (consequent-based condition - CC)
Trial: 34474038
Drug: PTG-100 (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTG-100 (150, 300, or 900 mg)
Trial: 33749997
Drug: Diclofenac-Hyaluronate Conjugate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diclofenac-Hyaluronate Conjugate (DF-HA) 30 mg, administered via intraarticular injection once every 4 weeks for 20 weeks (total of 6 injections)
Trial: 33749997
Drug: Placebo (citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (citric acid-sodium citrate buffered solution), administered via intraarticular injection once every 4 weeks for 20 weeks (total of 6 injections)
Trial: 32593960
Drug: Conventional overground
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional overground therapy (CT)
Trial: 37178149
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (control group)
Trial: 32554183
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) administration
Trial: 34292451
Drug: Pazopanib (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (median dose 150 mg daily for a median of 22 months)
Trial: 34047133
Drug: Child Compound
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Compound Endothelium Corneum (CCEC)
Trial: 33558250
Drug: Paediatric drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric drug RCTs published in 2017-2018
Trial: 32784188
Drug: Fatigue in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatigue in Teenagers on the InterNET, a web-based modular CFS/ME-specific cognitive behavioral therapy program supported by individualized clinical psychologist electronic consultations.
Trial: 34327798
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin
Trial: 37804189
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment
Trial: 33113295
Drug: LY-CoV555 2800
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY-CoV555 2800 mg
Trial: 33113295
Drug: LY-CoV555 700
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY-CoV555 700 mg
Trial: 33113295
Drug: LY-CoV555 7000
RxNorm normalized name: LYS
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LY-CoV555 7000 mg
Trial: 33113295
Drug: LY-CoV555 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY-CoV555 (all doses combined)
Trial: 36394295
Drug: Interactive web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive web-based self-management system for hypertension (daily measurement of BP and pulse, reports of well-being, symptoms, lifestyle, medication intake, side effects, reminders, motivational messages) for 8 weeks
Trial: 33549381
Drug: PRICE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRICE therapy (protection, rest, ice (cryotherapy at 3°C), compression (35 mm Hg), elevation)
Trial: 33657679
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg per day at night)
Trial: 36921619
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Chinese herbal medicine (CHM)
Trial: 33780573
Drug: CC-486 as
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 as maintenance therapy
Trial: 33780573
Drug: Venetoclax and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax and azacitidine combination
Trial: 36728194
Drug: Any therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any therapy
Trial: 33622382
Drug: Probiotics (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (840 mg bid) plus dietary fiber (30 g bid)
Trial: 33622382
Drug: Probiotics (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (840 mg bid) plus placebo
Trial: 33622382
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus dietary fiber (30 g bid)
Trial: 35338764
Drug: I gel
RxNorm normalized name: Omni Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I gel
Trial: 35834762
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by autologous stem-cell transplantation (ASCT)
Trial: 35439775
Drug: Blepharoexfoliation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blepharoexfoliation with tea tree oil 2% shampoo followed by eyelid scrubs with tea tree oil 2% shampoo twice a day for 8 weeks
Trial: 35439775
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with sham blepharoexfoliation and eyelid scrubs with tea tree oil 2% shampoo twice a day for 8 weeks
Trial: 33440080
Drug: Fotagliptin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fotagliptin (24 mg, once-daily for 14 days)
Trial: 33440080
Drug: Placebo (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once-daily for 14 days)
Trial: 35099523
Drug: Multicomponent vaccine
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent vaccine campaign
Trial: 38152404
Drug: Antifungal treatment
RxNorm normalized name: TOLNAFTATE 10 mg in 1 mL TOPICAL LIQUID [Liquid Antifungal Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal treatment
Trial: 35575751
Drug: Closed-loop therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop therapy (MiniMed 670G)
Trial: 34410322
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) - 12 weeks, thrice-weekly, supervised aerobic sessions at 85% to 95% of peak oxygen consumption (V̇o2)
Trial: 32271150
Drug: eHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth intervention for weekly monitoring of side effects using PRO-CTCAE questions
Trial: 32271150
Drug: eHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth intervention for weekly monitoring of side effects
Trial: 33238154
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg)
Trial: 34646885
Drug: Immediate Implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Implant Placement (IIP)
Trial: 34646885
Drug: Delayed Implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Implant Placement (DIP)
Trial: 35229767
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal therapy along with LLLT
Trial: 35229767
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal therapy only
Trial: 32751340
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment in conjunction with ozone gas therapy
Trial: 32751340
Drug: Standard periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard periodontal treatment
Trial: 36334223
Drug: Celery seed
RxNorm normalized name: CELERY SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celery seed extract (1.34 g per day)
Trial: 33161045
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity interval training (HIIT) - 4x4‐minute sessions, 3 times weekly for 4 weeks, followed by 3 home-based sessions weekly for 48 weeks
Trial: 33161045
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity continuous training (MICT) - 40 minutes, usual care, 3 times weekly for 4 weeks, followed by 3 home-based sessions weekly for 48 weeks
Trial: 37188468
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg/kg
Trial: 33857414
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for 1 year)
Trial: 34108716
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine
Trial: 34108716
Drug: BNT162b2 (Pfizer–BioNTech)
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (Pfizer–BioNTech) vaccine
Trial: 35261318
Drug: siponimod (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siponimod (2 mg/day)
Trial: 32114709
Drug: Subretinal injection
RxNorm normalized name: LUXTURNA Suspension for Subretinal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injection of conbercept (0.5 mg/0.05 ml)
Trial: 32114709
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (0.5 mg/0.05 ml)
Trial: 38293149
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Trial: 33471086
Drug: HTX-011 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (up to 60 mg bupivacaine/1.8 mg meloxicam) as the foundation of multimodal analgesia (MMA) regimen with ibuprofen (600 mg) and acetaminophen (1 g) every 3 hours for 72 hours.
Trial: 33471086
Drug: HTX-011 with
RxNorm normalized name: Human papillomavirus virus-like particles conjugated with ir700 dye au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 with scheduled ibuprofen and acetaminophen.
Trial: 35710091
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) plus Compression Therapy (CT)
Trial: 35710091
Drug: Calf Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf Muscle Exercise Training (CMET) plus Compression Therapy (CT)
Trial: 35710091
Drug: Compression Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression Therapy (CT) alone
Trial: 34258509
Drug: Odanacatib (anti‐cathepsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (anti‐cathepsin K monoclonal antibody)
Trial: 34258509
Drug: Romosozumab (anti‐sclerostin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (anti‐sclerostin monoclonal antibody)
Trial: 35549904
Drug: Midazolam/pethidine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam/pethidine combination
Trial: 33793143
Drug: Glycine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (3 g twice a day for 4 weeks)
Trial: 33793143
Drug: Glucose (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (placebo, 3 g twice a day for 4 weeks)
Trial: 32115159
Drug: Average monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Average monthly income
Trial: 35655483
Drug: Routine nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine nursing of gynecological malignant tumor chemotherapy
Trial: 32862577
Drug: Reduced glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced glutathione (GSH) treatment
Trial: 34371524
Drug: daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daridorexant 50 mg single dose
Trial: 34371524
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg single dose + daridorexant 50 mg single dose
Trial: 34371524
Drug: efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efavirenz 600 mg once a day for 10 days
Trial: 34371524
Drug: daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daridorexant 50 mg single dose + efavirenz 600 mg once a day for 2 days
Trial: 34964736
Drug: Oral mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mirtazapine (Control)
Trial: 35622185
Drug: MitraClip plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip plus optimal medical therapy (OMT)
Trial: 33054556
Drug: Tolcapone (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (a catechol-O-methyltransferase inhibitor)
Trial: 35543936
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical symptomatic treatment + NMES and rehabilitation training (Control group)
Trial: 32335860
Drug: Tongguan Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongguan Capsules (4.5 g/d) for 3 months
Trial: 32335860
Drug: Standard anti-platelet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-platelet, anti-coagulation and lipid-decreasing treatments
Trial: 35792926
Drug: 10-week, multimodal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-week, multimodal, bi-weekly exercise intervention (EG)
Trial: 32418174
Drug: Nux Vomica
RxNorm normalized name: Nux vomica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nux Vomica Capsule (NVC, 0.4 g, thrice daily) for 30 days
Trial: 33634794
Drug: Low Glycemic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Glycemic Index Treatment (LGIT)
Trial: 32467089
Drug: Two times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two times a day proton pump inhibitor (PPI)
Trial: 39515580
Drug: Magnetic Seizure
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Seizure Therapy (MST)
Trial: 33125448
Drug: Electroconvulsive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive Therapy (ECT) - Bitemporal (BT)
Trial: 33125448
Drug: Electroconvulsive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive Therapy (ECT) - Right Unilateral (RUL)
Trial: 38638400
Drug: Ranibizumab 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.2 mg
Trial: 34942508
Drug: Cultural dexterity
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultural dexterity curriculum (not specified dosage or duration)
Trial: 35367279
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 800 mg
Trial: 33864831
Drug: Daily SBP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SBP
Trial: 33785226
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pharmacologic treatment)
Trial: 32077207
Drug: Temelimab 6
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temelimab 6 mg/kg
Trial: 35488452
Drug: Cognitive‐Behavioral Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐Behavioral Therapy
Trial: 34003568
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy regimen (hydrocortisone 50 mg/6-h IV for 7 days, vitamin C 1.5 g/6-h IV for 4 days, thiamine 200 mg/12-h IV for 4 days)
Trial: 34003568
Drug: Hydrocortisone monotherapy
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone monotherapy (hydrocortisone 50 mg/6-h IV for 7 days)
Trial: 34003568
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy regimen
Trial: 33534617
Drug: Sitafloxacin 100
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100 mg qd
Trial: 33534617
Drug: Sitafloxacin 100
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin 100 mg bid
Trial: 33534617
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg qd
Trial: 34391281
Drug: Intramuscular stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular stimulation (IMS) to the pronator teres muscle, depth of 45-50 mm, 7 treatments over 7 weeks
Trial: 34391281
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received acupuncture needle at Li11, depth of 4-5 mm, 7 treatments over 7 weeks
Trial: 38271308
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of diuretics
Trial: 35318791
Drug: Mixed preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed preparation containing piperine, capsaicin, and curcumin, applied topically twice daily for 3 months.
Trial: 35318791
Drug: 5% minoxidil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% minoxidil, applied topically once daily for 3 months.
Trial: 38688118
Drug: Subcutaneous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ketamine
Trial: 32542733
Drug: Tigilanol tiglate
RxNorm normalized name: Tigilanol Tiglate
DrugBank: Tigilanol tiglate (DB18800)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigilanol tiglate (TT) 1 mg/mL injected intratumorally
Trial: 32762030
Drug: Silybum marianum
RxNorm normalized name: Silybum marianum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybum marianum extract (400 mg/d)
Trial: 33045501
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg orally every 8 hours during labor)
Trial: 35752091
Drug: 36 mg/ml
RxNorm normalized name: iodine 36 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg/ml e‐cigarette